Anti-Inflammatory and Antioxidant Effects of Liposoluble C60 at the Cellular, Molecular, and Whole-Animal Levels

References

• Kroto HW, Heath JR, O’Brien SC, et al. C60: buckminsterfullerene. Nature. 1985;318:162–163. doi:10.1038/318162a0
   Web of Science ®Google Scholar
• Diederich F, Ettl R, Rubin Y, et al. The higher fullerenes: isolation and characterization of C76, C84, C90, C94, and C70O, an oxide of D5h-C70. Science. 1991;252:548–551. doi:10.1126/science.252.5005.548
   PubMed Web of Science ®Google Scholar
• Palit DK, Sapre AV, Mittal JP, et al. Photophysical properties of the fullerenes, C60 and C70. Chem Phys Lett. 1992;195:1–6. doi:10.1016/0009-2614(92)85900-U
   Web of Science ®Google Scholar
• Kato S, Kikuchi R, Aoshima H, et al. Defensive effects of fullerene-C60/liposome complex against UVA-induced intracellular reactive oxygen species generation and cell death in human skin keratinocytes HaCaT, associated with intracellular uptake and extracellular excretion of fullerene-C60. J Photochem Photobiol B. 2010;98:144–151. doi:10.1016/j.jphotobiol.2009.11.015
   Web of Science ®Google Scholar
• Kato S, Aoshima H, Saitoh Y, et al. Fullerene-C60/liposome complex: defensive effects against UVA-induced damages in skin structure, nucleus and collagen type I/IV fibrils, and the permeability into human skin tissue. J Photochem Photobiol B. 2010;98:99–105. doi:10.1016/j.jphotobiol.2009.11.010
   Web of Science ®Google Scholar
• Galvan YP, Alperovich I, Zolotukhin P, et al. Fullerenes as anti-aging antioxidants. Current Aging Sci. 2017;10(1):56–67. doi:10.2174/1874609809666160921120008
   Google Scholar
• Mousavi SZ, Nafisi S, Maibach HI. Fullerene nanoparticle in dermatological and cosmetic applications. Nanomedicine. 2017;13(3):1071–1087. doi:10.1016/j.nano.2016.10.002
   PubMed Web of Science ®Google Scholar
• Inui S, Mori A, Ito M, et al. Reduction of conspicuous facial pores by topical fullerene: possible role in the suppression of PGE2 production in the skin. J Nanobiotechnology. 2014;12:6. doi:10.1186/1477-3155-12-6
   Web of Science ®Google Scholar
• Dellinger A, Zhou Z, Lenk R, et al. Fullerene nanomaterials inhibit phorbol myristate acetate–induced inflammation. Exp Dermatol. 2009;18:1079–1081. doi:10.1111/j.1600-0625.2009.00904.x
   PubMed Web of Science ®Google Scholar
• Inui S, Aoshima H, Nishiyama A, et al. Improvement of acne vulgaris by topical fullerene application: unique impact on skin care. Nanomedicine. 2011;7:238–241. doi:10.1016/j.nano.2010.09.005
   PubMed Web of Science ®Google Scholar
• Ryan JJ, Bateman HR, Stover A, et al. Fullerene nanomaterials inhibit the allergic response. J Immunol. 2007;179(1):665–672. doi:10.4049/jimmunol.179.1.665
   PubMed Web of Science ®Google Scholar
• Kopova I, Lavrentiev V, Vacik J, et al. Growth and potential damage of human bone-derived cells on fresh and aged fullerene C60 films. Int J Mol Sci. 2013;14(5):9182–9204. doi:10.3390/ijms14059182
   PubMed Web of Science ®Google Scholar
• Baati T, Bourasset T, Gharbi T, et al. The prolongation of the lifespan of rats by repeated oral administrtion of fullerene. Biomaterials. 2012;33(19):4936–4946. doi:10.1016/j.biomaterials.2012.03.036
   PubMed Web of Science ®Google Scholar
• Keykhosravi S, Rietveld IB, Couto B, Tmarit JL. [60] Fullerene for medical purposes, A purity criterion towards regulatory considerations. Materials. 2019;12(16):2571. doi:10.3390/ma12162571
   Web of Science ®Google Scholar
• Fromen CA, Kelley WJ, Fish MB, et al. Neutrophil–particle interactions in blood circulation drive particle clearance and alter neutrophil responses in acute inflammation. ACS Nano. 2017;11(11):10797–10807. doi:10.1021/acsnano.7b03190
   Web of Science ®Google Scholar
• Saito E, Kuo R, Pearson RM, et al. Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating inflammation. J Control Release. 2019;300:185–196. doi:10.1016/j.jconrel.2019.02.025
   PubMed Web of Science ®Google Scholar
• Larysa LM, Prylutska SV, Rudyk MP, et al. C60 Fullerene and its nanocomplexes with anticancer drugs modulate circulating phagocyte functions and dramatically increase ROS generation in transformed monocytes. Cancer Nano. 2018;9(1):8. doi:10.1186/s12645-017-0034-0
   Web of Science ®Google Scholar
• Dellinger AL, Zhou ZG, Kepley CL. A steroid-mimicking nanomaterial that mediates inhibition of human lung mast cell responses. Nanomedicine. 2014;10(6):1185–1193. doi:10.1016/j.nano.2014.02.006
   Web of Science ®Google Scholar
• Xinrong LI. A novel application of Carbon-60 and its activity assays. Patent application number:202010169138.X; 2020.
   Google Scholar
• Jaganjac M, Cipak A, Schaur RJ, et al. Pathophysiology of neutrophil-mediated extracellular redox reactions. Front Biosci. 2016;21:839–855. doi:10.2741/4423
   PubMed Web of Science ®Google Scholar
• Marzano AV, Borghi A, Wallach D, et al. A comprehensive review of neutrophilic diseases. Clin Rev Allergy Immunol. 2018;54(1):114–130. doi:10.1007/s12016-017-8621-8
   PubMed Web of Science ®Google Scholar
• Shershakova N, Baraboshkina E, Andreev S, et al. Anti-inflammatory effect of fullerene C60 in a mice model of atopic dermatitis. J Nanobiotechnology. 2016;14:8. doi:10.1186/s12951-016-0159-z
   PubMed Web of Science ®Google Scholar
• Tzeng SF, Lee JL, Kuo JS, et al. Effects of malonate C60 derivatives on activated microglia. Brain Res. 2002;940(1–2):61–68. doi:10.1016/S0006-8993(02)02592-1
   Web of Science ®Google Scholar
• Saisavoey T, Sangtanoo P, Reamtong O, et al. Antioxidant and anti-inflammatory effects of defatted rice bran (oryza sativa l.) protein hydrolysates on raw 264.7 macrophage cells. J Food Biochem. 2016;40(6):731–740. doi:10.1111/jfbc.12266
   Web of Science ®Google Scholar
• Song MY, Liu SF, Yin JF, et al. Interaction of human serum album and C60 aggregates in solution. Int J Mol Sci. 2011;12(8):4964–4974. doi:10.3390/ijms12084964
   PubMed Web of Science ®Google Scholar
• Fu XF, Fang YL, Zhao HL, et al. Size-dependent binding of pristine fullerene (nC60) nanoparticles to bovine/human serum albumin. J Mol Struct. 2018;1166:442–447. doi:10.1016/j.molstruc.2018.04.067
   Web of Science ®Google Scholar
• Liu QH, Jin L, Mahon BH, et al. Novel treatment of neuroinflammation against low back pain by soluble fullerol nanoparticles. Spine. 2013;38(17):1443–1451. doi:10.1097/BRS.0b013e31828fc6b7
   PubMed Web of Science ®Google Scholar
• Sastre J, Mannelli I, Reigada R. Effects of fullerene on lipid bilayers displaying different liquid ordering: acoarse-grained molecular dynamics study. Biochim Biophys Acta Gen Subj. 2017;1861(11 Pt A):2872–2882. doi:10.1016/j.bbagen.2017.08.004
   Web of Science ®Google Scholar
• Ha Y, Katz LE, Liljestrand HM. Distribution of fullerene nanoparticles between water and solid supported lipid membranes: thermodynamics and effects of membrane composition on distribution. Environ Sci Technol. 2015;49(24):14546–14553. doi:10.1021/acs.est.5b03339
   Web of Science ®Google Scholar
• Ikeda A, Kiguchi K, Shigematsu T, Nobusawa K, Kikuchi J-I, Akiyama M. Location of [60] fullerene incorporation in lipid membranes. Chem Commun. 2011;47(44):12095–12097. doi:10.1039/c1cc14650e
   Web of Science ®Google Scholar
• Dellinger A, Zhou ZG, Norton SK, Lenk R, Conrad D, Kepley CL. Uptake and distribution of fullerenes in human mast cells. Nanomedicine. 2010;6(4):575–582. doi:10.1016/j.nano.2010.01.008
   Web of Science ®Google Scholar
• Russ KA, Elvati P, Parsonage TL, et al. C60 fullerene localization and membrane interactions in RAW 264.7 immortalized mouse macrophages. Nanoscale. 2016;8(7):134–4144. doi:10.1039/C5NR07003A
   Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–1812. doi:10.1172/JCI200318921
   PubMed Web of Science ®Google Scholar
• Lau DC, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol. 2005;288(5):2031–2041. doi:10.1152/ajpheart.01058.2004
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–334. doi:10.1001/jama.286.3.327
   PubMed Web of Science ®Google Scholar
• Dehghan A, Kardys I, de Maat MP, et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes. 2007;56(3):872–878. doi:10.2337/db06-0922
   PubMed Web of Science ®Google Scholar
• Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc. 2005;105(9):409–416.
   PubMedGoogle Scholar
• Bray C, Bell LN, Liang H, et al. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. WMJ. 2016;115(6):317–321.
   PubMedGoogle Scholar
• Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, et al. Serum C-reactive protein in the prediction of cardiovascular diseases: overview of the latest clinical studies and public health practice. J Cell Physiol. 2018;233(11):8508–8525. doi:10.1002/jcp.26791
   PubMed Web of Science ®Google Scholar